CJC-1295 GHRH-R Research: GH Axis Signalling and Pituitary Cell Model Studies

CJC-1295 GHRH-R Research: Pharmacology Profile and Cell Model Studies CJC-1295 is a research compound studied in cell-based assay formats for its GHRH-R (class B GPCR) Gs/cAMP/PKA signalling with DAC albumin-binding modification. Published in vitro research characterises its molecular interactions, binding affinity profiles, and downstream pathway engagement in defined cell model systems under controlled laboratory conditions. Receptor Pharmacology and Mechanism of Action CJC-1295 acts as a selective agonist at the growth hormone-releasing hormone receptor (GHRH-R), a class B G protein-coupled receptor. The compound exhibits enhanced receptor binding characteristics compared to native GHRH through structural modifications that improve stability and binding kinetics. In vitro receptor binding studies demonstrate CJC-1295's high affinity interaction with GHRH-R, with binding constants indicating strong receptor engagement across multiple cell model systems. The peptide's mechanism involves activation of the Gs protein pathway, leading to adenylyl cyclase stimulation and subsequent cyclic adenosine monophosphate (cAMP) elevation. This cascade activates protein kinase A (PKA), which phosphorylates downstream transcription factors including CREB (cAMP response element-binding protein). Laboratory studies using fluorescence-based cAMP assays consistently demonstrate dose-dependent increases in intracellular cAMP levels following CJC-1295 treatment in GHRH-R-expressing cell lines. Drug Affinity Complex (DAC) Modification The drug affinity complex (DAC) component represents a critical pharmacological feature of CJC-1295. This modification involves conjugation with a maleimidopropionic acid linker that facilitates albumin binding through covalent interaction with cysteine residues. In vitro albumin binding studies reveal high-affinity interactions, with association constants indicating strong protein conjugation under physiological conditions. Cell-based pharmacokinetic modelling demonstrates that DAC modification significantly alters the compound's distribution and availability profiles in culture medium containing albumin. Binding kinetics studies show rapid albumin association followed by slower dissociation rates, creating a reservoir effect that maintains sustained receptor activation over extended timeframes in continuous perfusion cell culture systems. Cell Model Systems and Assay Development Primary Cell Models Research applications utilize various cell model systems expressing endogenous GHRH-R. Primary pituitary adenocyte cultures serve as physiologically relevant models for investigating CJC-1295's receptor pharmacology. These systems demonstrate robust cAMP responses to CJC-1295 stimulation, with EC50 values typically ranging in the nanomolar concentration range across multiple independent cell preparations. Immortalized cell lines transfected with human GHRH-R provide standardized platforms for reproducible pharmacological characterization. HEK293 and CHO cell systems expressing recombinant GHRH-R enable detailed receptor binding studies, competition assays, and downstream signalling pathway analysis under controlled experimental conditions. Signalling Pathway Analysis Advanced cell-based assays reveal CJC-1295's effects on multiple downstream signalling cascades beyond the primary Gs/cAMP pathway. Calcium mobilization studies in certain cell models indicate potential cross-talk with calcium-dependent signalling mechanisms. Phosphoproteomic analysis demonstrates PKA-mediated phosphorylation of numerous substrate proteins involved in transcriptional regulation and metabolic enzyme activity. Real-time PCR analysis of GHRH-R-expressing cell cultures treated with CJC-1295 reveals time-dependent changes in gene expression profiles. Transcriptional targets include immediate early genes and factors involved in growth hormone synthesis and secretion pathways, demonstrating functional coupling between receptor activation and downstream cellular responses. Comparative Receptor Pharmacology Structure-activity relationship studies comparing CJC-1295 with native GHRH and other analogues reveal distinct pharmacological profiles. Receptor binding competition assays demonstrate CJC-1295's enhanced binding affinity, with improved receptor residence time compared to unmodified peptides. Functional selectivity studies indicate preserved efficacy at GHRH-R while maintaining selectivity over related class B GPCRs. Enzyme kinetics analysis of adenylyl cyclase activation shows CJC-1295 produces sustained enzymatic activity compared to transient responses observed with native GHRH. This prolonged activation profile correlates with extended cAMP elevation and downstream pathway engagement in cell-based functional assays. Research Summary In vitro pharmacological characterization establishes CJC-1295 as a potent GHRH-R agonist with unique albumin-binding properties through DAC modification. Cell model studies demonstrate nanomolar binding affinity, robust Gs/cAMP/PKA pathway activation, and sustained receptor engagement. The compound's pharmacological profile in various cell-based assay systems supports its utility as a research tool for investigating GHRH-R signalling mechanisms and downstream cellular responses in controlled laboratory environments. All content is intended for in vitro laboratory research purposes only. Not for human or animal consumption. Not intended to diagnose, treat, cure, or prevent any condition. Hexarelin TB-500 Epithalon Ipamorelin Tirzepatide CJC-1295 DAC PT-141 Semaglutide Selank BPC-157 Sermorelin Melanotan 2 IGF LR3 Tesamorelin AICAR IGF-DES GHRP 2 Albuterol Tamoxifen Letrozole Clomiphene Tadalafil Clenbuterol Anastrozole Finasteride Exemestane Sildenafil Yohimbine Bacteriostatic Water Recent Posts Melanotan 2 (MT2): Mechanism, Research, and Safety Considerations Ipamorelin: The Selective GHRP, Explained Tesamorelin: The GHRH Analog Studied for Visceral Fat Sermorelin: The Original GHRH Analog, Explained CJC-1295: How the GHRH Analog Works, and What Research Shows Already a customer? Sign In Create Account All products on this site are for Research, Development use only. Products are Not for Human consumption of any kind. The statements made within this website have not been evaluated by the US Food and Drug Administration. The statements and the products of this company are not intended to diagnose, treat, cure or prevent any disease. ElementSarms is a chemical supplier. ElementSarms is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic act. ElementSarms is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic act. Sarms Stacks Research Liquids Albuterol 5MG/ML | 30ML with dropper Anastrozole 1.5MG/ML | 30ML with dropper Clomiphene 50MG/ML | 30ML with dropper Finasteride 5MG/ML | 30ML with dropper Letrozole 3.5 MG/ML | 30ML with dropper LiquiCia 30MG/ML | 30ML with dropper LiquiCia T50 50MG/ML | 30ML with dropper LiquiClen 200MCG/ML | 30ML with dropper Liquistane / Exemestane 25MG/ML | 30ML with dropper LiquiTamo 20MG/ML | 30ML with dropper LiquiVia 25MG/ML | 30 ML with dropper T3 LIOTHYRONINE 200MCG/ML | 30ML with dropper Toremifene Citrate 60MG/ML | 30ML with dropper Yohimbine HCL 10MG/ML | 30ML with dropper Research Peptides Aicar 50MG BPC-157 + TB-500 Blend 2mg ea/ 4MG BPC-157 5MG CJC-1295 + DAC 2MG CJC-1295 | No DAC 2MG Epithalon 10MG Frag Premium 176-191 5MG GHK-CU Copper Peptide 50MG GHRP-2 5MG GHRP-6 5MG Hexarelin 5MG IGF-1 DES 1MG IGF-1 LR3 1MG Ipamorelin 5MG Melanotan 2 10MG NAD+ 500MG PT-141 / Bremelanotide 10MG GLP-1/GIP/GCG (RT) Selank 5MG GLP1 (SM) Sermorelin 5MG TB-500 5MG GIP/GLP-1 (TZ) PDE5 Inhibitors GLP-1 Diluents Bacteriostatic Water 10ML

CJC-1295 GHRH-R Research: Growth Hormone Axis Regulation Studies In Vitro Research Overview CJC-1295 is a research compound studied in cell-based assay formats for its GHRH-R (class B GPCR) Gs/cAMP/PKA signalling with DAC albumin-binding modification. Published in vitro research characterises its molecular interactions, binding affinity profiles, and downstream pathway engagement in defined cell model systems under controlled laboratory conditions. The compound represents a modified analogue of growth hormone-releasing hormone (GHRH) engineered for extended stability and receptor interaction studies. Research applications focus on understanding pituitary somatotroph cell responses, receptor binding kinetics, and intracellular signalling cascade activation. Laboratory investigations utilise established cell lines including CHO cells transfected with human GHRH receptors, primary pituitary cell cultures, and immortalised somatotroph models for pharmacological characterisation. Receptor Pharmacology and Mechanism of Action GHRH Receptor Binding Characteristics CJC-1295 acts via GHRH-R (class B GPCR) Gs/cAMP/PKA signalling with DAC albumin-binding modification. Competitive radioligand binding assays demonstrate nanomolar affinity for the GHRH receptor, with binding constants typically ranging from 0.5-2.0 nM in transfected cell systems. The compound exhibits selectivity for GHRH receptors over other related class B GPCRs including VIP, PACAP, and glucagon receptors. Saturation binding experiments reveal specific, high-affinity interaction with GHRH receptor sites. Scatchard analysis indicates single-site binding kinetics with Hill coefficients approximating unity, suggesting non-cooperative binding behaviour. Competition studies using native GHRH(1-29) confirm receptor specificity and demonstrate comparable binding affinity profiles. Signal Transduction Pathways Upon receptor binding, CJC-1295 activates Gs protein-coupled adenylyl cyclase pathways, resulting in elevated intracellular cyclic adenosine monophosphate (cAMP) concentrations. Real-time cAMP accumulation assays show dose-dependent responses with EC50 values typically in the 0.1-1.0 nM range in responsive cell models. Protein kinase A (PKA) activation follows cAMP elevation, as demonstrated through phosphorylation of downstream substrates including CREB (cAMP response element-binding protein). Western blot analysis reveals time-dependent CREB phosphorylation at Ser133 residues, indicating functional coupling to transcriptional regulatory mechanisms. Albumin Binding Modifications DAC Conjugation Effects The drug affinity complex (DAC) modification involves lysine conjugation that facilitates albumin binding, extending compound stability in cell culture systems. Surface plasmon resonance studies demonstrate high-affinity albumin interaction with dissociation constants in the micromolar range. This modification does not significantly impair GHRH receptor binding affinity based on competitive binding analyses. Albumin-bound fraction studies using equilibrium dialysis techniques show extensive protein binding (>95%) in serum-containing culture media. Despite high albumin affinity, receptor activation remains robust, suggesting effective dissociation kinetics allow productive receptor engagement. Cell Model Applications Somatotroph Cell Systems Primary rat anterior pituitary cell cultures serve as physiologically relevant models for CJC-1295 receptor pharmacology studies. These heterogeneous cultures contain native somatotroph populations expressing endogenous GHRH receptors. Flow cytometry analysis confirms somatotroph identity through growth hormone immunostaining. Immortalised GH3 and GH4C1 cell lines provide reproducible experimental platforms for mechanistic studies. These rat pituitary-derived cells maintain GHRH receptor expression and cAMP responsiveness, enabling standardised assay protocols for compound evaluation. Transfected Cell Models CHO-K1 cells stably transfected with human GHRH receptor cDNA offer homogeneous receptor expression for detailed pharmacological characterisation. Receptor density quantification through radioligand saturation binding typically yields 50,000-200,000 binding sites per cell, providing robust assay sensitivity. HEK293 transient transfection systems allow rapid screening of receptor variants and mutants to probe structure-activity relationships. Luciferase reporter constructs driven by cAMP response elements enable high-throughput functional assessment of signalling pathway activation. Research Summary CJC-1295 represents a valuable research tool for investigating GHRH receptor pharmacology and growth hormone regulatory mechanisms in vitro. The compound demonstrates high-affinity, selective GHRH receptor binding with potent activation of Gs/cAMP/PKA signalling cascades. DAC albumin-binding modifications extend compound stability without compromising receptor interaction. Established cell models including primary pituitary cultures, immortalised cell lines, and transfected systems provide complementary platforms for comprehensive pharmacological characterisation. These in vitro systems enable detailed investigation of receptor binding kinetics, signal transduction mechanisms, and downstream cellular responses relevant to growth hormone axis regulation. All content is intended for in vitro laboratory research purposes only. Not for human or animal consumption. Not intended to diagnose, treat, cure, or prevent any condition. Hexarelin TB-500 Epithalon Ipamorelin Tirzepatide CJC-1295 DAC PT-141 Semaglutide Selank BPC-157 Sermorelin Melanotan 2 IGF LR3 Tesamorelin AICAR IGF-DES GHRP 2 Albuterol Tamoxifen Letrozole Clomiphene Tadalafil Clenbuterol Anastrozole Finasteride Exemestane Sildenafil Yohimbine Bacteriostatic Water Recent Posts Melanotan 2 (MT2): Mechanism, Research, and Safety Considerations Ipamorelin: The Selective GHRP, Explained Tesamorelin: The GHRH Analog Studied for Visceral Fat Sermorelin: The Original GHRH Analog, Explained CJC-1295: How the GHRH Analog Works, and What Research Shows Already a customer? Sign In Create Account All products on this site are for Research, Development use only. Products are Not for Human consumption of any kind. The statements made within this website have not been evaluated by the US Food and Drug Administration. The statements and the products of this company are not intended to diagnose, treat, cure or prevent any disease. ElementSarms is a chemical supplier. ElementSarms is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic act. ElementSarms is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic act. Sarms Stacks Research Liquids Albuterol 5MG/ML | 30ML with dropper Anastrozole 1.5MG/ML | 30ML with dropper Clomiphene 50MG/ML | 30ML with dropper Finasteride 5MG/ML | 30ML with dropper Letrozole 3.5 MG/ML | 30ML with dropper LiquiCia 30MG/ML | 30ML with dropper LiquiCia T50 50MG/ML | 30ML with dropper LiquiClen 200MCG/ML | 30ML with dropper Liquistane / Exemestane 25MG/ML | 30ML with dropper LiquiTamo 20MG/ML | 30ML with dropper LiquiVia 25MG/ML | 30 ML with dropper T3 LIOTHYRONINE 200MCG/ML | 30ML with dropper Toremifene Citrate 60MG/ML | 30ML with dropper Yohimbine HCL 10MG/ML | 30ML with dropper Research Peptides Aicar 50MG BPC-157 + TB-500 Blend 2mg ea/ 4MG BPC-157 5MG CJC-1295 + DAC 2MG CJC-1295 | No DAC 2MG Epithalon 10MG Frag Premium 176-191 5MG GHK-CU Copper Peptide 50MG GHRP-2 5MG GHRP-6 5MG Hexarelin 5MG IGF-1 DES 1MG IGF-1 LR3 1MG Ipamorelin 5MG Melanotan 2 10MG NAD+ 500MG PT-141 / Bremelanotide 10MG GLP-1/GIP/GCG (RT) Selank 5MG GLP1 (SM) Sermorelin 5MG TB-500 5MG GIP/GLP-1 (TZ) PDE5 Inhibitors GLP-1 Diluents Bacteriostatic Water 10ML